10.1111/j.1476-5381.2009.00441.x [DOI] [PMC free article] [PubMed] [Google Scholar] Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, DAlessio DA, Haupt A (2018) LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept
Local Medical Supervision Unlike national telehealth services where your provider might be 1,000 miles away, BlueWater offers face-to-face consultations when you want them, same-day or next-day appointments if concerns arise, in-person problem-solving and adjustments, and providers who know you personallynot just your file
Glucagon-like peptide-1 (GLP-1) analogues are medications primarily used in the treatment of type 2 diabetes and obesity, which mimic the action of the natural hormone GLP-1, which is necessary for regulating glucose levels in the body
The Motley Fool has positions in and recommends Amgen and Merck
